Journal article
Cardiovascular events in patients with Fabry disease: Natural history data from the Fabry Registry
MR Patel, F Cecchi, M Cizmarik, I Kantola, A Linhart, K Nicholls, J Strotmann, J Tallaj, TC Tran, ML West, D Beitner-Johnson, A Abiose
Journal of the American College of Cardiology | ELSEVIER SCIENCE INC | Published : 2011
Abstract
Objectives: These analyses were designed to determine the incidence of major cardiovascular (CV) events and the natural history of CV complications in patients with Fabry disease. Background: Fabry disease, a genetic disorder caused by deficiency of alpha-galactosidase A activity, is associated with CV dysfunction. Methods: Major CV events (myocardial infarction, heart failure, or cardiac-related death) were analyzed in 2,869 Fabry Registry patients during the natural history period (i.e., before enzyme replacement therapy or among patients who never received therapy). Multivariate logistic regression analyses were performed to identify significant predictors of CV events. Results: Eighty-th..
View full abstractGrants
Funding Acknowledgements
The Fabry Registry is sponsored by Genzyme Corporation (Cambridge, Massachusetts). Drs. Patel, Strotmann, and Abiose served on the Genzyme-sponsored Fabry Registry Boards of Advisors. Drs. Cecchi and Linhart have received research support and speaking fees from Genzyme and from Shire HGT. Ms. Cizmarik and Dr. Beitner-Johnson are full-time employees of Genzyme. Dr. Kantola has received speaking fees and travel funds from Genzyme and from Shire HGT. Dr. Nicholls has received travel and research support from Genzyme, Shire HGT, and Amicus Therapeutics and serves on the Fabry Outcome Survey (FOS) International Advisory Board. Dr. Strotmann has received research support and speaking fees from Genzyme. Dr. West has received speaking fees, research funding, and/or consultant fees from Genzyme, Shire HGT, Amicus Therapeutics, and Sumitomo Pharma. All other authors have reported that they have no relationships to disclose.